A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program
Respiratory syncytial virus (RSV) is a major cause of respiratory illness in older adults. During the 2023–2024 respiratory season, Ontario was the first and only province in Canada to launch a publicly funded RSV vaccination program for older adults. A process evaluation of the program was complete...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2550089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849224241327636480 |
|---|---|
| author | Reed Morrison Janice Sarmiento Jamie Park Gillian Lim Christina Renda Michael Whelan Allison McGeer Tara Harris Sarah E. Wilson |
| author_facet | Reed Morrison Janice Sarmiento Jamie Park Gillian Lim Christina Renda Michael Whelan Allison McGeer Tara Harris Sarah E. Wilson |
| author_sort | Reed Morrison |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is a major cause of respiratory illness in older adults. During the 2023–2024 respiratory season, Ontario was the first and only province in Canada to launch a publicly funded RSV vaccination program for older adults. A process evaluation of the program was completed to better understand the experiences of the local Public Health Units (PHUs) and long-term care homes (LTCHs) implementing the program. Two process evaluation surveys, one each for PHUs and LTCHs, and a separate immunization coverage survey for LTCHs were distributed. The coverage survey found that 58.5% of residents, among all those living in LTCHs responding to the survey, received the RSV vaccine. Process evaluation surveys found that both PHUs and LTCHs perceived the RSV vaccine to be of lower priority than influenza and COVID-19 vaccines. There was also concordance between PHU and LTCH respondents regarding barriers to program implementation, which included temporary guidance against routine co-administration, a detailed informed consent procedure, and the timing of program roll-out. An additional barrier for LTCH respondents was vaccine hesitancy among staff and residents or their substitute decision makers. Facilitators to program implementation were effective communication with program partners, availability of technical resources, and programmatic supports. These evaluation findings are being shared to assist other jurisdictions in their planning of potential older adult or LTCH vaccination programs, including RSV vaccination. An important consideration for future program implementation is how to improve vaccine confidence in LTCH residents and staff in a rapidly changing vaccine landscape. |
| format | Article |
| id | doaj-art-a66ef08aa07d475c90f015ef5a3b37c0 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-a66ef08aa07d475c90f015ef5a3b37c02025-08-25T13:15:27ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2550089A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination programReed Morrison0Janice Sarmiento1Jamie Park2Gillian Lim3Christina Renda4Michael Whelan5Allison McGeer6Tara Harris7Sarah E. Wilson8Department of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Microbiology, Sinai Health System, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaDepartment of Communicable Disease Control, Public Health Ontario, Toronto, Ontario, CanadaRespiratory syncytial virus (RSV) is a major cause of respiratory illness in older adults. During the 2023–2024 respiratory season, Ontario was the first and only province in Canada to launch a publicly funded RSV vaccination program for older adults. A process evaluation of the program was completed to better understand the experiences of the local Public Health Units (PHUs) and long-term care homes (LTCHs) implementing the program. Two process evaluation surveys, one each for PHUs and LTCHs, and a separate immunization coverage survey for LTCHs were distributed. The coverage survey found that 58.5% of residents, among all those living in LTCHs responding to the survey, received the RSV vaccine. Process evaluation surveys found that both PHUs and LTCHs perceived the RSV vaccine to be of lower priority than influenza and COVID-19 vaccines. There was also concordance between PHU and LTCH respondents regarding barriers to program implementation, which included temporary guidance against routine co-administration, a detailed informed consent procedure, and the timing of program roll-out. An additional barrier for LTCH respondents was vaccine hesitancy among staff and residents or their substitute decision makers. Facilitators to program implementation were effective communication with program partners, availability of technical resources, and programmatic supports. These evaluation findings are being shared to assist other jurisdictions in their planning of potential older adult or LTCH vaccination programs, including RSV vaccination. An important consideration for future program implementation is how to improve vaccine confidence in LTCH residents and staff in a rapidly changing vaccine landscape.https://www.tandfonline.com/doi/10.1080/21645515.2025.2550089Immunizationimmunization programrespiratory syncytial virusRSVevaluationlong term care |
| spellingShingle | Reed Morrison Janice Sarmiento Jamie Park Gillian Lim Christina Renda Michael Whelan Allison McGeer Tara Harris Sarah E. Wilson A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program Human Vaccines & Immunotherapeutics Immunization immunization program respiratory syncytial virus RSV evaluation long term care |
| title | A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program |
| title_full | A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program |
| title_fullStr | A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program |
| title_full_unstemmed | A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program |
| title_short | A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program |
| title_sort | process evaluation of ontario canada s 2023 24 older adult rsv vaccination program |
| topic | Immunization immunization program respiratory syncytial virus RSV evaluation long term care |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2550089 |
| work_keys_str_mv | AT reedmorrison aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT janicesarmiento aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT jamiepark aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT gillianlim aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT christinarenda aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT michaelwhelan aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT allisonmcgeer aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT taraharris aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT sarahewilson aprocessevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT reedmorrison processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT janicesarmiento processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT jamiepark processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT gillianlim processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT christinarenda processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT michaelwhelan processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT allisonmcgeer processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT taraharris processevaluationofontariocanadas202324olderadultrsvvaccinationprogram AT sarahewilson processevaluationofontariocanadas202324olderadultrsvvaccinationprogram |